Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
|Videos|May 15, 2018
Parkinson Disease: When There’s No Fight Left
Author(s)Bobby Lazzara, MD
An update on the prevalence and features of demoralization in patients with PD.
Advertisement
The findings indicated demoralization can compromise a patient’s motor dysfunction and while it is pervasive, it is different from depression. The primary difference is an inability to cope in patients who are demoralized. The authors stated, “Treatment approaches are also different, making it important to identify demoralization in patients with PD.”
Reference
1. Koo BB, Chow CA, Shah DR.
Advertisement
Related to this article
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
2
From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026
3
Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms
4
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
5